Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small–Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)

Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small–Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)

Alain Vergnenègre,1 Victor Basse,2 Gwenaelle Le Garff,3 Olivier Bylicki,4 Catherine Dubos-Arvis,5 Bénédicte Comet,6 Marie Marcq,7 Jacques Le Treut,8 Jean-Bernard Auliac,9 Anne Madroszyk,10 Gislaine Fraboulet,11 Jacky Crequit,12 Pascal Thomas,13 Nicolas Paleiron,14 Is...

Full description

Bibliographic Details
Main Authors: Vergnenègre A, Basse V, Le Garff G, Bylicki O, Dubos-Arvis C, Comet B, Marcq M, Le Treut J, Auliac JB, Madroszyk A, Fraboulet G, Crequit J, Thomas P, Paleiron N, Monnet I
Format: Article
Language:English
Published: Dove Medical Press 2019-12-01
Series:Cancer Management and Research
Subjects:
lung cancer
squamous non-small cell
antiangiogenic treatments
Online Access:https://www.dovepress.com/potential-antiangiogenic-treatment-eligibility-of-patients-with-squamo-peer-reviewed-article-CMAR

Internet

https://www.dovepress.com/potential-antiangiogenic-treatment-eligibility-of-patients-with-squamo-peer-reviewed-article-CMAR

Similar Items